Hims & Hers Health (NYSE: HIMS) made waves yesterday when it revealed plans to offer a lower priced alternative to Novo Nordisk (NYSE: NVO)’s Wegovy pill. The telehealth company aims to sell this version, which mimics the active ingredient semaglutide, for just $49 in the first month and $99 afterward. That undercuts Novo’s branded pill, which lists at $149 per month, by a wide margin.
Let’s step back and look at how this unfolded. Novo Nordisk introduced the pill form of Wegovy in the U.S. just weeks earlier, in early January. The drug belongs to a class called GLP-1s, which help people lose weight by curbing appetite and regulating blood sugar. Demand has exploded, with 170,000 users signing up quickly, but the high cost keeps many potential customers away, especially those without good insurance coverage. Hims, known for its app-based consultations and mail order prescriptions, spotted an opening. Customers answer online questions, get matched with a doctor, and receive the medication at home, all without a clinic visit.
The announcement hit markets hard. Hims shares jumped as much as 15% during Thursday trading, riding excitement about grabbing a slice of the booming obesity treatment sector. Investors saw the pricing as a smart play to attract budget conscious users in a space where obesity affects over 40% of U.S. adults. Yet the gains faded fast. Novo fired back swiftly, calling the product illegal and vowing legal action to protect its intellectual property and patient safety. Hims closed the day down 3.8% at a 12 month low, and shares dropped another 5% this morning.
Novo’s response carried weight because of the history here. The Danish company has tangled with Hims before, ending a short-lived partnership last year over concerns about compounded drugs marketed under the guise of personalization. Compounded versions mix ingredients to match a prescription, often allowed during shortages, but Novo argues most sales now skirt regulations. They claim these copies use untested ingredients, sometimes from foreign sources, risking quality and effectiveness. Hims frames its offering as tailored care, adjusting doses for individual needs like nausea side effects common with GLP-1s. Still, Novo’s legal threats underscore a core tension: big pharma guards patents fiercely while telehealth firms push affordability and access.Â
This corporate narrative reveals deeper business dynamics. Hims built its model on convenience for everyday issues like hair loss or erectile dysfunction, serving over a million subscribers. Weight loss fits perfectly, promising revenue growth in a market headed toward tens of billions. A year on their plan costs about $1,188, versus over $1,700 for Novo’s, making it appealing for long term users. But legal battles could slow that momentum. Novo has filed over 100 lawsuits against compounders and telehealth providers, targeting everyone from pharmacies to medical spas. They worry copycats erode trust in FDA approved drugs and invite safety issues.
For Hims, the strategy bets on volume over margins. Lower prices draw in masses sidelined by costs, easing obesity related burdens like diabetes or heart disease on healthcare systems. CEO moves signal confidence, but stock volatility shows investor nerves about court fights and regulatory scrutiny. Past clashes, including a class action lawsuit tied to the prior partnership split, add layers of risk. Novo, meanwhile, balances blockbuster sales with defense. Wegovy and sibling Ozempic fuel their growth, but rivals like Eli Lilly’s Mounjaro loom large.Â
Both companies navigate a shifting landscape. Telehealth thrives on digital speed, letting providers decide treatments independently. Big pharma leans on research billions and brand loyalty. Regulators watch compounded drugs closely, balancing innovation with safety. If Hims prevails legally, it could spark price wars, much like generics reshaped cholesterol meds decades ago. More options mean broader access, helping everyday people tackle weight issues affordably.
The back and forth will play out in courts and boardrooms. Hims pushes forward with its platform, stressing patient choice. Novo doubles down on enforcement, safeguarding its edge. Shareholders watch sales data and rulings closely, as this saga shapes who controls obesity care’s future growth.
